Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome

Ann N Y Acad Sci. 1998 May 13:841:203-6. doi: 10.1111/j.1749-6632.1998.tb10929.x.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Humans
  • Middle Aged
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / genetics
  • Myasthenia Gravis / physiopathology
  • Point Mutation
  • Quinidine / adverse effects
  • Quinidine / therapeutic use*
  • Receptors, Cholinergic / genetics*
  • Syndrome

Substances

  • Receptors, Cholinergic
  • Quinidine